<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Conferences</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Merck &amp; Co. prepares and tests new IL4I1 inhibitors</title>
      <description>
        <![CDATA[Recent evidence has suggested that secreted L-amino-acid oxidase, also known as interleukin-4-induced protein 1 (IL4I1), is involved in aromatic amino acid metabolism, as a key immunosuppressive enzyme expressed by tumor-associated myeloid cells, thus suppressing T-cell activation and proliferation within the tumor microenvironment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730454</guid>
      <pubDate>Fri, 17 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730454-merck-and-co-prepares-and-tests-new-il4i1-inhibitors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/NCI-Tumor-Microenvironment.webp?t=1668701295" type="image/png" medium="image" fileSize="536658">
        <media:title type="plain">Tumor microenvironment</media:title>
        <media:description type="plain">A traditional view of the tumor microenvironment (TME). Neurons are increasingly being recognized as an important part of the TME in many cancer types. Credit: NCI</media:description>
      </media:content>
    </item>
    <item>
      <title>Peptide GFRAL/RET antagonists against GDF15-induced effects of chemotherapy</title>
      <description>
        <![CDATA[Syracuse University recently presented a comprehensive preclinical program describing the rational design and optimization of peptide antagonists targeting the GDF15/GFRAL/RET receptor complex to mitigate nausea, emesis, anorexia and wasting associated with chemotherapy-induced stress signaling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730453</guid>
      <pubDate>Fri, 17 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730453-peptide-gfral-ret-antagonists-against-gdf15-induced-effects-of-chemotherapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/molecule-dropper-tubes-abstract-science.webp?t=1731606498" type="image/jpeg" medium="image" fileSize="206914">
        <media:title type="plain">Art concept for drug research</media:title>
      </media:content>
    </item>
    <item>
      <title>Biohaven reports details on discovery of BHV-2100</title>
      <description>
        <![CDATA[Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of rodents and humans. Its activation triggers acute pain, making drugs that target TRPM3 a potential approach to alleviate pain. Biohaven Ltd.’s BHV-2100 is the only selective TRPM3 antagonist in clinical development. The company recently disclosed the work leading to its discovery and early development, as well as the chemical structure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730377</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730377-biohaven-reports-details-on-discovery-of-bhv-2100</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Neurology-neuropathic-nerve-pain.webp?t=1691077523" type="image/jpeg" medium="image" fileSize="160260">
        <media:title type="plain">Man holding raised arm with illustrated overlay of nerves</media:title>
      </media:content>
    </item>
    <item>
      <title>Early development of Olema and Aurigene’s OP-3136 for breast cancer</title>
      <description>
        <![CDATA[The discovery and development of new histone lysine acetyltransferase KAT6 inhibitors is a significant advancement in the management of breast cancer. Investigators from Olema Pharmaceuticals Inc. and Aurigene Oncology Ltd. recently presented data for their KAT6 inhibitor, OP-3136, as an approach for breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730376</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730376-early-development-of-olema-and-aurigenes-op-3136-for-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NCI-Breast-Cancer-Cells.webp?t=1678814973" type="image/png" medium="image" fileSize="2351536">
        <media:title type="plain">Breast cancer cells.</media:title>
        <media:description type="plain">This is a histological slide of cancerous breast tissue stained with H&amp;amp;E and magnified to 200x. The pink "riverways" are normal connective tissue, and the blue is cancer cells. Credit: Cecil Fox, National Cancer Institute, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Ru@TiO2 protects kidneys from acute injury</title>
      <description>
        <![CDATA[Acute kidney injury (AKI), although sometimes reversible, is associated with an increased risk of chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Reactive oxygen species (ROS) contribute to maladaptive repair and progression to CKD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730348</guid>
      <pubDate>Tue, 14 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730348-rutio2-protects-kidneys-from-acute-injury</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/Kidney-dialysis-AI.webp?t=1589217904" type="image/png" medium="image" fileSize="203534">
        <media:title type="plain">Kidney illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel caspase-2 inhibitor shows in vivo neuroprotective effects</title>
      <description>
        <![CDATA[Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). This fragment accumulates at synapses, disrupts glutamatergic signaling and contributes to cognitive impairment in vivo.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730346</guid>
      <pubDate>Tue, 14 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730346-novel-caspase-2-inhibitor-shows-in-vivo-neuroprotective-effects</link>
    </item>
    <item>
      <title>Lipid reading: Street not deaf to ACC data</title>
      <description>
        <![CDATA[Abstracts released ahead of the American College of Cardiology meeting held in late March in New Orleans, along with the start of dosing near the end of January in Novartis AG’s phase IIb trial with siRNA therapy DII-235, also known as BW-20829, perked up the already-lively lipids/heart space.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730223</guid>
      <pubDate>Mon, 13 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730223-lipid-reading-street-not-deaf-to-acc-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Cholesterol.webp?t=1667944246" type="image/png" medium="image" fileSize="326836">
        <media:title type="plain">Cholesterol plaque in artery</media:title>
      </media:content>
    </item>
    <item>
      <title>Biohaven’s BHV-1450 shows promise for pemphigus vulgaris</title>
      <description>
        <![CDATA[Pemphigus vulgaris (PV) is a life-threatening autoimmune disease affecting the skin, causing painful erosions on the skin and mucous membranes. PV is caused by IgG4 autoantibodies that target desmoglein 1 (DSG1) and DSG3, which are involved in keratinocyte cell-cell adhesion. There is a high unmet medical need for PV, since current therapies rely on systemic corticosteroids and immunosuppressants.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730331</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730331-biohavens-bhv-1450-shows-promise-for-pemphigus-vulgaris</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/antibodies-lab-research.webp?t=1717686528" type="image/jpeg" medium="image" fileSize="266442">
        <media:title type="plain">Lab glassware and antibodies art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>LCC-6 characterized as an antifibrotic and copper chelator agent</title>
      <description>
        <![CDATA[Copper overload within the body may lead to cancer, neurodegenerative diseases, inflammation or fibrosis, among others. Copper chelation is an effective strategy to counteract this potential overload; mitochondria play an important role, as they are the main copper-using organelles in the cells. Copper chelators have been developed, but they have shown some undesired off-target effects and low specificity, which suggests the need for new therapies in the field.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730244</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730244-lcc-6-characterized-as-an-antifibrotic-and-copper-chelator-agent</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Research-pipette-dropper-test-tube-pink.webp?t=1775746909" type="image/jpeg" medium="image" fileSize="420680">
        <media:title type="plain">Photo of pipette with test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>Selective CBL-B inhibitor with improved safety profile disclosed</title>
      <description>
        <![CDATA[CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune responses. In cancer, however, this inhibitory role can impair the immune system’s capacity to detect and eradicate tumor cells. Researchers from Genentech Inc. presented the design and optimization of a series of CBL-B-targeting molecular glues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730243</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730243-selective-cbl-b-inhibitor-with-improved-safety-profile-disclosed</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Targeted-cancer-cell.webp?t=1748961673" type="image/jpeg" medium="image" fileSize="966728">
        <media:title type="plain">Cancer cell in the cross-hairs</media:title>
      </media:content>
    </item>
    <item>
      <title>VB-19055 exerts antihypertensive effects</title>
      <description>
        <![CDATA[Chinese researchers from Zhejiang Yangli Pharmaceutical Technology Co. Ltd. have presented data on an aldosterone synthase inhibitor, VB-19055. Inhibiting aldosterone synthase (CYP11B2) could lead to a potential treatment for cardiovascular-renal-metabolic disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730190</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730190-vb-19055-exerts-antihypertensive-effects</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Blood-pressure-monitor.webp?t=1669673487" type="image/png" medium="image" fileSize="262797">
        <media:title type="plain">Blood pressure monitor</media:title>
      </media:content>
    </item>
    <item>
      <title>Hematopoietic stem cell research points to leukemia’s early roots</title>
      <description>
        <![CDATA[Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference, held March 26, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730205</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730205-hematopoietic-stem-cell-research-points-to-leukemias-early-roots</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells.webp?t=1588880225" type="image/png" medium="image" fileSize="554020">
        <media:title type="plain">Cancer and blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Next-generation anti-CD30 ADC outperforms brentuximab vedotin</title>
      <description>
        <![CDATA[Researchers from Mabqi SAS presented the preclinical profile of MQI-181, an antibody-drug conjugate (ADC) composed of a human anti-CD30 antibody (18D03) linked to the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable MC-VC-PAB linker, with a drug-antibody ratio of 4.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730169</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730169-next-generation-anti-cd30-adc-outperforms-brentuximab-vedotin</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-antibody-therapy.webp?t=1744729079" type="image/jpeg" medium="image" fileSize="215111">
        <media:title type="plain">Illustration of antibodies targeting cancer cell </media:title>
      </media:content>
    </item>
    <item>
      <title>Hematopoietic stem cell research points to leukemia’s early roots</title>
      <description>
        <![CDATA[Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference, held March 26, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730162</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730162-hematopoietic-stem-cell-research-points-to-leukemias-early-roots</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells.webp?t=1588880225" type="image/png" medium="image" fileSize="554020">
        <media:title type="plain">Cancer and blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Longhorn reports long-acting peptidoglycan-targeted mAb for sepsis</title>
      <description>
        <![CDATA[At the World Vaccine Congress this week, Longhorn Vaccines & Diagnostics LLC presented the preclinical characterization of LHNVD-501, a half-life-extended, humanized IgG monoclonal antibody (mAb) targeting peptidoglycan (PGN). PGN is a conserved structural component shared across bacterial species and an upstream driver of sepsis, as well as metabolic disease, autoimmune disorders and neurodegeneration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730094</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730094-longhorn-reports-long-acting-peptidoglycan-targeted-mab-for-sepsis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Monoclonal-antibody-therapy.webp?t=1731516507" type="image/jpeg" medium="image" fileSize="136228">
        <media:title type="plain">Illustration of monoclonal antibody hovering between doctor's hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Hematopoietic stem cell research points to leukemia’s early roots</title>
      <description>
        <![CDATA[Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference (ICKSH 2026), held March 26, 2026. Work in Dick’s lab has found acute myeloid leukemia (AML) HSCs that harbor preleukemic mutations long before any disease diagnosis. These insights have enabled predictive models that could identify individuals at elevated AML risk years before the onset of outright disease, opening the door to new prevention strategies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730055</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730055-hematopoietic-stem-cell-research-points-to-leukemias-early-roots</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells.webp?t=1588880225" type="image/png" medium="image" fileSize="554020">
        <media:title type="plain">Cancer and blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis</title>
      <description>
        <![CDATA[Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the treatment of atopic dermatitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730042</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730042-infinimmune-presents-preclinical-data-on-anti-il-22-antibody-for-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/Antibodies-blue-orange-close-up.webp?t=1774969563" type="image/jpeg" medium="image" fileSize="944048">
        <media:title type="plain">3D illustration of antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>HXN-1023 drives robust anti-inflammatory responses in atopic dermatitis models</title>
      <description>
        <![CDATA[Dysregulated type 2 immune responses are central in atopic dermatitis (AD) pathophysiology. Key cytokine IL-13 drives epidermal barrier dysfunction and inflammation, while IL-31 mediates pruritus via activation of sensory neurons. Both represent clinically validated, complementary targets addressing both inflammation and itch in AD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730040</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730040-hxn-1023-drives-robust-anti-inflammatory-responses-in-atopic-dermatitis-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/dermatologic-skin-layer-regenerative.webp?t=1745258161" type="image/jpeg" medium="image" fileSize="334698">
        <media:title type="plain">Skin, tissue layer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>TY-1 ameliorates hypertrophy in mice with HCM</title>
      <description>
        <![CDATA[Hypertrophic cardiomyopathy (HCM) is a condition that limits tolerance to exercise and predisposes people to sudden cardiac death due to mutations in sarcomeric genes. Researchers from Cedars-Sinai Medical Center have tested TY-1, a chemically modified oligonucleotide-based drug inspired by the previously tested EV-YF1, in mice with HCM.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730039</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730039-ty-1-ameliorates-hypertrophy-in-mice-with-hcm</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cardiology-genomics-genetics-illustration.webp?t=1751985662" type="image/jpeg" medium="image" fileSize="693008">
        <media:title type="plain">Illustration of heart analysis for DNA and drug impacts</media:title>
      </media:content>
    </item>
    <item>
      <title>NAV-242 bispecific antibody supports quarterly dosing in HS</title>
      <description>
        <![CDATA[Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by dysregulated T-cell-mediated immune responses and suboptimal outcomes with current therapies. Increased expression of OX40 and OX40L in lesional HS skin suggests a contributory role for this pathway in disease-associated inflammation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730036</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730036-nav-242-bispecific-antibody-supports-quarterly-dosing-in-hs</link>
    </item>
    <item>
      <title>AAD 2026: Targeted oral therapies challenge injected biologics</title>
      <description>
        <![CDATA[Data presented at the 2026 American Academy of Dermatology (AAD) meeting have put the spotlight on the arrival of target-selective oral therapies that are set to challenge injected biologics in terms of efficacy, while offering greater convenience and improving access to treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729951</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729951-aad-2026-targeted-oral-therapies-challenge-injected-biologics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Oral-medication.webp?t=1652383335" type="image/png" medium="image" fileSize="350602">
        <media:title type="plain">Oral medication</media:title>
      </media:content>
    </item>
    <item>
      <title>MAP4K1 inhibitor enhances antitumor immune responses</title>
      <description>
        <![CDATA[Researchers from Blueprint Medicines Corp. and F. Hoffmann-La Roche Ltd. presented the preclinical characterization of BLU-852, a selective MAP4K1 inhibitor developed as a potential immunotherapeutic agent for cancer treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730019</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730019-map4k1-inhibitor-enhances-antitumor-immune-responses</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-tumor-tcells-attacking.webp?t=1764171255" type="image/jpeg" medium="image" fileSize="851669">
        <media:title type="plain">T cells attacking cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Iambic’s IAM-1363 shows promise in HER2+ cancers</title>
      <description>
        <![CDATA[Using Iambic Therapeutics’ AI/HTE platform, researchers at the company have engineered a next-generation HER2 inhibitor with superb selectivity for HER2, as well as broad mutant coverage and brain penetrance. The compound, IAM-1363, binds to HER2 in a type II DFG-out conformation, which represents the first reported type II HER2 tyrosine kinase inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730018</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730018-iambics-iam-1363-shows-promise-in-her2-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-HER2-positive-ductal-carcinoma.webp?t=1774883272" type="image/jpeg" medium="image" fileSize="1439224">
        <media:title type="plain">Photomicrograph of immunohistochemistry for HER2</media:title>
        <media:description type="plain">Photomicrograph of immunohistochemistry for HER2, showing positive cell membrane staining in this infiltrating ductal carcinoma.</media:description>
      </media:content>
    </item>
    <item>
      <title>BRD9 PROTAC shows efficacy in sarcoma and leukemia models</title>
      <description>
        <![CDATA[In both acute myeloid leukemia (AML) and synovial sarcoma (SS), targeting BRD9 disrupts oncogenic transcriptional programs, including MYC, leading to reduced proliferation and induction of apoptosis. Researchers from Pamplona Therapeutics (Shenzhen) Co. Ltd. reported the discovery and preclinical efficacy profile of XYD-270, a BRD9-targeting PROTAC, in models of SS and AML.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730016</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730016-brd9-protac-shows-efficacy-in-sarcoma-and-leukemia-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/leukemia-lymphoma-blood-cancer.webp?t=1724424490" type="image/jpeg" medium="image" fileSize="506006">
        <media:title type="plain">Art concept for hematologic cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>CGT-19 as an approach to expand CAR T-cell therapy accessibility</title>
      <description>
        <![CDATA[The use of CAR T-cell therapy has transformed outcomes for relapsed or refractory B-cell malignancies, but access to it remains extremely limited in some countries. Cartogene Therapeutics Pvt Ltd. aimed to address this need by in-licensing CGT-19, a CD19 CAR T construct from Vector Biomed Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730015</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730015-cgt-19-as-an-approach-to-expand-car-t-cell-therapy-accessibility</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/CAR-CD19-binding.webp?t=1665503757" type="image/png" medium="image" fileSize="2301092">
        <media:title type="plain">CD19 binding </media:title>
      </media:content>
    </item>
    <item>
      <title>Forx Therapeutics discloses discovery, structure of PARG inhibitor FORX-428</title>
      <description>
        <![CDATA[Forx Therapeutics AG presented a comprehensive preclinical medicinal chemistry and translational profiling program describing the optimization of potent and selective poly(ADP-ribose) glycohydrolase inhibitors, which led to the identification of FORX-428, currently in phase I clinical trials. The company also disclosed the chemical structure of the compound.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730014</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730014-forx-therapeutics-discloses-discovery-structure-of-parg-inhibitor-forx-428</link>
    </item>
    <item>
      <title>Molecular signatures show subtypes in neurodegenerative diseases</title>
      <description>
        <![CDATA[Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the condition advances. Yet the biological divide between those who experience this cognitive decline and those who do not has remained an open question. Are they different conditions or simply stages of the same disease?]]>
      </description>
      <guid>http://www.bioworld.com/articles/730013</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730013-molecular-signatures-show-subtypes-in-neurodegenerative-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neuron-nerve-cell-dna-genetics.webp?t=1774882830" type="image/jpeg" medium="image" fileSize="414335">
        <media:title type="plain">Illustration of a nerve cell with DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>Small-molecule TREM2 agonist advances to treat Alzheimer’s</title>
      <description>
        <![CDATA[Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), scientists focused on TREM2, a microglial receptor that regulates immune responses, exploring new ways to address neuroinflammation.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/730054</guid>
      <pubDate>Fri, 27 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730054-small-molecule-trem2-agonist-advances-to-treat-alzheimers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Alzheimers-disease-vs-healthy-brain-neurons.webp?t=1774539087" type="image/jpeg" medium="image" fileSize="461468">
        <media:title type="plain">Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques</media:title>
      </media:content>
    </item>
    <item>
      <title>VY-AD-4116 and VY-AD-4226, dual-targeted synthetic antimicrobials</title>
      <description>
        <![CDATA[Researchers from the Indian Institute of Technology Bombay have reported the preclinical development of a new synthetic antimicrobial class incorporating organic metallophores, which yielded two optimized leads – VY-AD-4-11-6 and VY-AD-4-22-6 – from a 30-compound SAR series.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729998</guid>
      <pubDate>Fri, 27 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729998-vy-ad-4116-and-vy-ad-4226-dual-targeted-synthetic-antimicrobials</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/bacterial-biofilm-illustration.webp?t=1706776019" type="image/jpeg" medium="image" fileSize="415150">
        <media:title type="plain">Illustration of rod-shaped and spherical bacteria forming a biofilm</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-986482 induces pan-IKZF degradation and robust tumor growth inhibition</title>
      <description>
        <![CDATA[IKZF1-4 are transcription factors that regulate cellular differentiation, proliferation and survival. At the American Chemical Society (ACS) Spring 2026 meeting this week in Atlanta, Bristol Myers Squibb Co. detailed the identification and preclinical profile of BMS-986482, a next-generation investigational cereblon E3 ligase modulator (CELMoD) degrader designed to target IKZF1-4 factors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729997</guid>
      <pubDate>Fri, 27 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729997-bms-986482-induces-pan-ikzf-degradation-and-robust-tumor-growth-inhibition</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Green-molecules.webp?t=1763673659" type="image/jpeg" medium="image" fileSize="568196">
        <media:title type="plain">Green molecules</media:title>
      </media:content>
    </item>
  </channel>
</rss>
